CS
Therapeutic Areas
Novo Nordisk Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Wegovy HD (semaglutide 7.2mg) | Obesity | Approved |
| Glucose-sensitive insulin analogue | Type 1 & 2 Diabetes | Phase 1 |
| siRNA GalXC-GYS2 | Type 2 Diabetes | Phase 1 |
| Amylin analogue (subcutaneous) | Obesity | Phase 1 |
| CNP analogue | Heart Failure | Phase 1 |
| NLRP3 inhibitor | Cardiovascular Disease | Phase 1 |
| siRNA SLC25A5 | MASH | Phase 1 |
| Oral antibody fragment | Haemophilia | Phase 1 |
Leadership Team at Novo Nordisk
LF
Lars Fruergaard Jørgensen
President and CEO
KM
Karsten Munk Knudsen
EVP and CFO
MS
Marcus Schindler
EVP Research & Early Development, CSO
DM
David Moore
EVP Corporate Development
HW
Henrik Wulff
EVP Product Supply, Quality & IT
DL
Doug Langa
EVP North America
MD
Mike Doustdar
EVP International Operations
MH
Martin Holst Lange
EVP Development
LH
Ludovic Helfgott
EVP Rare Disease
TS
Thomas Senderovitz
SVP Data Science